Imugene Expands Immunotherapy Platform, Announces Licensing of Oncolytic Virus CF33 from City of Hope...

A biotech company headquartered in Australia, Imugene Limited (ASX: IMU) develops new and novel immunotherapies that seek to harness the cancer patients’ immune system...
Imugene Presents New HER-Vaxx Data At ESMO World Congress On Gastrointestinal Cancer

Imugene Presents New HER-Vaxx Data At ESMO World Congress On Gastrointestinal Cancer

A biotechnology company listed on the Australian Stock Exchange (ASX), Imugene Limited (ASX: IMU) develops cancer immunotherapies targeting B-cell peptide vaccines. The immunotherapies developed...

A Look at Imugene’s robust pipeline of B-Cell Vaccines for Cancer Immunotherapy

An Australian-headquartered clinical stage immuno-oncology company, Imugene Limited (ASX: IMU) has a robust pipeline of B cell vaccines aimed at treating a variety of...
IMU

An Insight into Imugene’s Unique Platform Technology

Imugene Limited (ASX: IMU) is a clinical-stage immuno-oncology company headquartered in Australia that is engaged in developing a range of immunotherapies used to treat...

A Glimpse At Biotech Company, Imugene Limited

A biotechnology company with operations in America and Europe, Imugene Limited (ASX: IMU) deals with the development of cancer immunotherapies targeting B-cell peptide vaccines....
5,589FansLike
2,639FollowersFollow
429SubscribersSubscribe

Latest News

Editorial

Facebook Comments